Solid Tumors Clinical Trials in Rochester, Minnesota

6 studies are recruiting for solid tumors in Rochester, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

   The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-u…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic in Rochester, Minnesota ( Site 0002), Rochester, Minnesota

   Locations

   782 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT03486873 on ClinicalTrials.gov

2. A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

   This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial w…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Local Institution - 0129, Rochester, Minnesota

   Locations

   58 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07492680 on ClinicalTrials.gov

3. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

   The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanc…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Rochester, Minnesota

   Locations

   42 in total

   Run by

   ORIC Pharmaceuticals

   See if you can join NCT05315700 on ClinicalTrials.gov

4. A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

   This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorec…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota

   Locations

   100 in total

   Run by

   Mirati Therapeutics Inc.

   See if you can join NCT07415031 on ClinicalTrials.gov

5. Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study

   To collect and analyze specimens that will correlate with clinical outcomes such as acute and late toxicities, quality of life, local control, and survival of patients treated with photon/proton therapy.

   Stage

   Not phased

   Ages

   Any age

   Site

   Mayo Clinic, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT02457962 on ClinicalTrials.gov

6. Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

   The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Mayo Clinic - Rochester, Rochester, Minnesota

   Locations

   9 in total

   Run by

   Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

   See if you can join NCT06963281 on ClinicalTrials.gov